DV
Dividend Vision

ELDN Stock — Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. (ELDN)

Updated October 16, 2026.

ELDN is a Stock. Total return is -99.9% over the past 12.1 years, 466.1 points behind SPY at 366.2%.

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology therapies targeting the CD40 ligand pathway, primarily to prevent transplant rejection in kidney and xenotransplantation procedures and to treat amyotrophic lateral sclerosis. The company does not currently distribute to shareholders. Eledon appeals to investors seeking exposure to early-stage biotech development with a focus on immunological and transplant-related treatments.

ELDN dividend yield and income

Price as of 2026-10-16.

The payment date is 10/05/2020.

ELDN performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 12.1 years, 466.1 points behind SPY at 366.2%. Over the past year its total return — price change plus distributions reinvested — is -25.3%. Its deepest 1-year drawdown was 68.1%.

WindowTotal returnCAGR
1M-20.2%—
3M-44.5%—
6M-42.9%—
YTD41.1%—
1Y-25.3%—
2Y CAGR—-14.70%
3Y CAGR—11.20%
5Y CAGR—-17.70%
10Y CAGR—-38.30%
Since inception (12.1 years)-99.9%-46.20%

ELDN key facts

Asset type
Stock
Asset class
Equity
Inception date
09/17/2014
Distribution frequency
None
Last close
$2.13 (as of 2026-10-16)
Market cap
$173,086,254
Average volume
801391.0
Payment date
10/05/2020
Beta
0.851
Payout ratio
0.0%
Forward P/E
5.3908
EPS
$-0.90

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ELDN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 68.1%.

Who may consider ELDN — and who may not

It is a weaker fit for investors who need monthly cash flow (ELDN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ELDN

Tagged: Healthcare.

Frequently asked questions

Does ELDN pay monthly?

No. ELDN does not currently distribute.

When does ELDN pay a dividend?

ELDN does not currently distribute. The payment date is 10/05/2020.

How has ELDN performed?

Total return is -99.9% over the past 12.1 years, 466.1 points behind SPY at 366.2%. Over the past year its total return — price change plus distributions reinvested — is -25.3%. Its deepest 1-year drawdown was 68.1%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.